Tirzepatide (TZP) is a dual glucose-dependent insulinotropic (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved by the Food and Drug Administration (FDA) for the management of diabetes since May 2022 and obesity since November 2023. Here, GLP1R is linked to diabetes mellitus.